USA: A secondary analysis of the 68-week STEP TEENS trial, published in Diabetes Care, found that semaglutide 2.4 mg ...

Novo Nordisk’s GLP-1/amylin combo has topped blockbuster semaglutide in a phase 3 Type 2 diabetes trial, though CagriSema ...

Novo Nordisk (CPSE:NOVO B) has used legal and regulatory pressure to push Hims & Hers to drop plans for a compounded oral ...

In patients with type 2 diabetes and heart failure, those assigned oral semaglutide had reduced risk for heart failure events ...

Oral semaglutide lowers heart failure events in people with type 2 diabetes and existing heart failure without increasing ...

A Novo executive noted that many customers are unaware that the company already makes oral semaglutide for type 2 diabetes ...

Please provide your email address to receive an email when new articles are posted on . The GLP-1 receptor agonist semaglutide may not only add another therapeutic option for chronic kidney disease, ...

We read with interest the Article by Marc P Bonaca and colleagues, which showed that the GLP-1 receptor agonist semaglutide improves walking distance by 13% in patients with peripheral artery disease ...

Semaglutide reduced major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease regardless of baseline adiposity. Cardiovascular benefit was largely ...

HealthDay News — Lowering the annual cost of semaglutide by 18% (from $8604 to $7055) or making the current cash price available to all patients would make semaglutide cost-effective, according to a ...

One study found that semaglutide helps to improve liver health in people with metabolic dysfunction-associated steatohepatitis, a serious form of fatty liver disease. The use of semaglutide, a ...

Semaglutide, the active ingredient in the weight-loss medications Ozempic and Wegovy, offers substantial cardiovascular ...